Document is current

Article History

Received: 28 June 2025

Accepted: 14 July 2025

First Online: 28 July 2025

Declarations

:

: The authors have no competing interests to declare that are relevant to the content of this article. Financial Disclosures for the previous 12 months: MP received speaking honoraria (lectures) by Candoro ethics Austria. FC, PS, and K Schwarzová have no conflict of interest. AZ has participated in meetings sponsored by, received speaking honoraria or travel funding from Biogen, Merck, Novartis, Sanofi-Genzyme, Janssen and Teva. FDP has participated in meetings sponsored by, received honoraria (lectures, advisory boards, consultations) or travel funding from Amgen, Bayer, Biogen, Janssen, Merck, Neuraxpharm, Novartis, Sanofi-Genzyme, Teva, Celgene and Roche. AD reports honoraria from Novo Nordisk, Roche, Bial, and AbbVie. K Seppi reports honoraria from the International Parkinson and Movement Disorders Society, grants from the FWF Austrian Science Fund, the Michael J. Fox Foundation, and the International Parkinson and Movement Disorder Society, as well as personal fees from Teva, UCB, Lundbeck, AOP Orphan Pharmaceuticals AG, AbbVie, Bial, Roche, and Grünenthal outside the submitted work. BH reports honoraria from Novartis AG, AbbVie, Bial and grants from the Austrian science fund (FWF) outside the submitted work.

: The study protocol was approved by the local ethics committees. All participants gave written informed consent prior to their participation. The interviews and examinations were carried out in accordance with the principles expressed in the Declaration of Helsinki of 1975 and its later amendments. On behalf of all co-authors, the first and corresponding author confirm that all authors have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

: Informed consent was obtained from all individual participants included in the study.